June 19 Dova Pharmaceuticals Inc:
* Dova Pharmaceuticals Inc sees IPO of upto 4.06 million shares of common stock to be priced between $15 and $17 per share - SEC filing
* Dova Pharmaceuticals Inc says intends to use about $19.0 million of IPO proceeds to fund commercialization of Avatrombopag
* Dova Pharmaceuticals Inc says intends to use about $21 million of IPO proceeds to fund clinical trials of Avatrombopag for additional indications
* Dova Pharmaceuticals Inc says intends to use about $30 million of IPO proceeds as repayment to EISAI of a portion of our obligations under the EISAI note Source text: (bit.ly/2rHxnhD) Further company coverage:
RPT-INVESTMENT FOCUS-Stocks flying, oil crying as 2017 hits halfway point
LONDON, June 23 World stocks could be about to record their best start to a year since 1998, when global markets were recovering from the Asian crisis, while oil and the dollar are facing their worst first-half in years.
Roche says new haemophilia drug cuts bleed rate by 87 pct
ZURICH, June 26 Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday.